Abstract
Introduction: Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age 5years. Ewing's sarcoma family tumors include classic Ewing’s sarcoma, primitive neuroectodermal tumour and Askin tumor ES is the second most common variety of primary bone cancer in adolescents and young adults. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. Although the survival rate of ES patients has improved, their prognosis remains unsatisfactory, and the treatment of ES is still challenging specially in age group below 3 years. Patients and methods: A Retrospective study of children below 3 years with a diagnosis Ewing Sarcoma/PNET treated at our CCHE from July 2009 till December 2018. Results: A review of 46 patients with age ranged from 3 months to 3 years, Mean of age was 1.8. Primary site was Osseous and extraosseus in 23 infant patients for each. Main site was mainly axial in 28 cases (60.8%). Cases were treated according to COG protocol. Infantile Ewing sarcoma OS and EFS at 5-years OS were 75.5% and 66.7%. Conclusion: Patients below 3 years represent an unusually young age group. Conclusion: ES/PNET in age below 3 years is a unique age group with a different management and outcome.
Highlights
Ewing sarcoma is an aggressive malignancy of bone and soft tissue
Ewing sarcoma is malignant tumor of bone and soft tissue and it accounts for 3% of all pediatric malignancies [1]
Differences in the Overall & the Event-free survival between age groups were estimated according to the Kaplan–Meier method with 95% confidence interval (CI), and the p-values were reported from the two-sided log rank test
Summary
Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age5years. Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age. The survival rate of ES patients has improved, their prognosis remains unsatisfactory.The treatment of ES is still challenging specially in age group below 3 years. Ewing sarcoma is malignant tumor of bone and soft tissue and it accounts for 3% of all pediatric malignancies [1]. It represents the second most common primary malignant bone cancer in children and adolescents [2]. ESFT are highly aggressive and patient prognosis is typically very poor so treatment remains a challenge [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
